CD56 regulates human NK cell cytotoxicity through Pyk2

  1. Justin T Gunesch
  2. Amera L Dixon
  3. Tasneem AM Ebrahim
  4. Melissa Berrien-Elliott
  5. Swetha Tatineni
  6. Tejas Kumar
  7. Everardo Hegewisch-Solloa
  8. Todd A Fehniger
  9. Emily M Mace  Is a corresponding author
  1. Baylor College of Medicine, United States
  2. Columbia University, United States
  3. Barnard College, United States
  4. Washington University, United States
  5. Rice University, United States
  6. Washington University School of Medicine, United States

Abstract

Human natural killer (NK) cells are defined as CD56+CD3−. Despite its ubiquitous expression on human NK cells the role of CD56 (NCAM) in human NK cell cytotoxic function has not been defined. In non-immune cells, NCAM can induce signaling, mediate adhesion, and promote exocytosis through interactions with focal adhesion kinase (FAK). Here we demonstrate that deletion of CD56 on the NK92 cell line leads to impaired cytotoxic function. CD56-knockout (KO) cells fail to polarize during immunological synapse (IS) formation and have severely impaired exocytosis of lytic granules. Phosphorylation of the FAK family member Pyk2 at tyrosine 402 is decreased in NK92 CD56-KO cells, demonstrating a functional link between CD56 and signaling in human NK cells. Cytotoxicity, lytic granule exocytosis, and the phosphorylation of Pyk2 are rescued by the reintroduction of CD56. These data highlight a novel functional role for CD56 in stimulating exocytosis and promoting cytotoxicity in human NK cells.

Data availability

All data generated or analysed during this study are included in the manuscript and supporting files.

Article and author information

Author details

  1. Justin T Gunesch

    Pediatrics, Baylor College of Medicine, Houston, United States
    Competing interests
    The authors declare that no competing interests exist.
  2. Amera L Dixon

    Pediatrics, Columbia University, New York, United States
    Competing interests
    The authors declare that no competing interests exist.
  3. Tasneem AM Ebrahim

    Biology, Barnard College, New York, United States
    Competing interests
    The authors declare that no competing interests exist.
  4. Melissa Berrien-Elliott

    Medicine, Washington University, St Louis, United States
    Competing interests
    The authors declare that no competing interests exist.
  5. Swetha Tatineni

    Rice University, Houston, United States
    Competing interests
    The authors declare that no competing interests exist.
  6. Tejas Kumar

    Pediatrics, Baylor College of Medicine, Houston, United States
    Competing interests
    The authors declare that no competing interests exist.
  7. Everardo Hegewisch-Solloa

    Pediatrics, Columbia University, New York, United States
    Competing interests
    The authors declare that no competing interests exist.
  8. Todd A Fehniger

    Dept of Medicine, Division of Oncology, Washington University School of Medicine, St Louis, United States
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-8705-2887
  9. Emily M Mace

    Pediatrics, Columbia University, New York, United States
    For correspondence
    em3375@cumc.columbia.edu
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-0226-7393

Funding

National Institutes of Health (R01AI137073)

  • Emily M Mace

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Human subjects: Peripheral blood NK cells were obtained in accordance with the Declaration of Helsinki with the written and informed consent of all participants under the guidance of the Institutional Review Boards of Baylor College of Medicine (IRB H-30487) and Columbia University (IRB AAAR7377).

Copyright

© 2020, Gunesch et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 6,387
    views
  • 736
    downloads
  • 47
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Justin T Gunesch
  2. Amera L Dixon
  3. Tasneem AM Ebrahim
  4. Melissa Berrien-Elliott
  5. Swetha Tatineni
  6. Tejas Kumar
  7. Everardo Hegewisch-Solloa
  8. Todd A Fehniger
  9. Emily M Mace
(2020)
CD56 regulates human NK cell cytotoxicity through Pyk2
eLife 9:e57346.
https://doi.org/10.7554/eLife.57346

Share this article

https://doi.org/10.7554/eLife.57346

Further reading

    1. Cell Biology
    2. Immunology and Inflammation
    Alejandro Rosell, Agata Adelajda Krygowska ... Esther Castellano Sanchez
    Research Article

    Macrophages are crucial in the body’s inflammatory response, with tightly regulated functions for optimal immune system performance. Our study reveals that the RAS–p110α signalling pathway, known for its involvement in various biological processes and tumourigenesis, regulates two vital aspects of the inflammatory response in macrophages: the initial monocyte movement and later-stage lysosomal function. Disrupting this pathway, either in a mouse model or through drug intervention, hampers the inflammatory response, leading to delayed resolution and the development of more severe acute inflammatory reactions in live models. This discovery uncovers a previously unknown role of the p110α isoform in immune regulation within macrophages, offering insight into the complex mechanisms governing their function during inflammation and opening new avenues for modulating inflammatory responses.

    1. Cell Biology
    Affiong Ika Oqua, Kin Chao ... Alejandra Tomas
    Research Article

    G protein-coupled receptors (GPCRs) are integral membrane proteins which closely interact with their plasma membrane lipid microenvironment. Cholesterol is a lipid enriched at the plasma membrane with pivotal roles in the control of membrane fluidity and maintenance of membrane microarchitecture, directly impacting on GPCR stability, dynamics, and function. Cholesterol extraction from pancreatic beta cells has previously been shown to disrupt the internalisation, clustering, and cAMP responses of the glucagon-like peptide-1 receptor (GLP-1R), a class B1 GPCR with key roles in the control of blood glucose levels via the potentiation of insulin secretion in beta cells and weight reduction via the modulation of brain appetite control centres. Here, we unveil the detrimental effect of a high cholesterol diet on GLP-1R-dependent glucoregulation in vivo, and the improvement in GLP-1R function that a reduction in cholesterol synthesis using simvastatin exerts in pancreatic islets. We next identify and map sites of cholesterol high occupancy and residence time on active vs inactive GLP-1Rs using coarse-grained molecular dynamics (cgMD) simulations, followed by a screen of key residues selected from these sites and detailed analyses of the effects of mutating one of these, Val229, to alanine on GLP-1R-cholesterol interactions, plasma membrane behaviours, clustering, trafficking and signalling in INS-1 832/3 rat pancreatic beta cells and primary mouse islets, unveiling an improved insulin secretion profile for the V229A mutant receptor. This study (1) highlights the role of cholesterol in regulating GLP-1R responses in vivo; (2) provides a detailed map of GLP-1R - cholesterol binding sites in model membranes; (3) validates their functional relevance in beta cells; and (4) highlights their potential as locations for the rational design of novel allosteric modulators with the capacity to fine-tune GLP-1R responses.